Преимущества терапии сахарного диабетабазальным аналогом инсулина детемир (Левемир®)

1. International Diabetes Federation Atlas, 4th edition, 2009.

2. Дедов И.И. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. - 2011. - № 1. - С. 95-105.

3. Kurtzhals P. et al. // J Pharm Sci. - 1996. - № 85. - Р. 304-308.

4. Hermansen К., Fontaine P., Kukolja К.К. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy forpatients with type 1 diabetes // Diabetologia. - 2004. - № 47(4). - Р. 622-629.

5. Standi E., Roberts A., Lang H., et al. The 12-month efficacy and safety of insulin detemirand NPH insulin in basal-bolustherapy for the treatment of type 1 diabetes // Diabetes Technology Therapeutics. - 2004. - № 6(5). - Р. 579-88.

6. Philis-Tsimikas A., Charpentier G., Per Clauson et al. Comparison of One-daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes // Clinical Therapeutics. - 2006. - V. 28 (10). - Р. 1569-1581.

7. Dornhorst A., et al. Safety and efficacy of insulin detmir in clinical practice: 14-week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE // European cohort Inte Journal of Clin Practice. - 2007.

8. Hollander P. et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basalbolus regimen with mealtime insulin aspart in patients with type 2 diabetes // Сд Ther. - 2008. - № 20(11). - Р. 1976-1987.

9. Verges B. et al. Long-acting insulin analogue therapy initiation and follow-up by healthcare practitioners in patients with T2DM uncontrolled with oral antidiabetic drugs: the LIGHT study. Novo Nordisk book of abstracts // EASD. - 2009; poster № 972.

10. Hollander P. et al. Efficacy and safety of insulin detemir once-daily in combination with sitagliptin and metformin: the Transition™ randomised controlled trial // Diabetes, Obesity and Metabolism. - Published online, 3 December 2010.